Sign in
Taking people in United StatesPhase 1

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Key facts

Who runs it
Innoviva Specialty Therapeutics
Where
Galveston, Greenville, Los Angeles, and San Diego, United StatesSee the 4 sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
48 people, planned
Starts
30 Dec 2026
Expected to end
20 May 2028
Type of study
Interventional, 6 groups
Treatments tested
  • Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)
  • Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)
  • Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)
  • Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
Record updated
6 October 2026

Who can take part

Age
1 day to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Patient from birth (defined as post-natal age of 7 days) to <18 years of age at the time of written informed consent (and assent, if applicable) and is hospitalized
  • Patient and/or parent(s) or legal guardian(s) have provided the written informed consent and/or assent
  • Patient has confirmed or suspected diagnosis of ABC infection and requires IV antibiotics for treatment
  • Patient has expected survival of 30 days after enrollment in the study
  • If patient is an individual of childbearing potential or reproductive potential, then the patient must remain abstinent OR must utilize one of the highly effective methods of contraception (ie, condom, combined oral contraceptive, implant, or injectable) from at least 30 days prior to screening until at least 30 days after administration of the last dose of study drug

Who cannot take part

  • Patient is in refractory septic shock at the time of enrollment, defined as persistent hypotension despite adequate fluid resuscitation or vasopressive therapy
  • Patient is receiving peritoneal dialysis or cardiopulmonary bypass
  • Patient has received blood transfusion within 24 hours of study drug administration
  • Patient (or patient's mother, if the patient is being breastfed) is using or will need to use any medications known to inhibit organic anion transporter 1 (OAT1) (eg, probenecid)
  • Patient (or patient's mother, if the patient is being breastfed) has participated in a clinical study involving investigational medication or an investigational device within the last 30 days or 5 half-lives, whichever is longer, prior to first dose of the study drug
  • Patient (or patient's mother, if the patient is being breastfed) has previously received durlobactam
  • Patient (or patient's mother, if the patient is being breastfed) has received sulbactam and/or sulbactam-containing regimens (eg, Unasyn) within 72 hours of first dose of the study drug
  • Patient (or patient's mother, if the patient is being breastfed) has received amphotericin B within 7 days of first dose of the study drug
  • Patient has history of significant hypersensitivity or allergic reaction to any β-lactam, any contraindication to the excipients used in the formulation, or any contraindication to the use of β-lactam antibiotics. Note: For β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment
  • Patient has any condition that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data
  • Patient has an age-appropriate estimated creatinine clearance that indicates renal impairment
  • Patient has the following laboratory results at Screening:; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3×upper limit of normal (ULN) and,; Total bilirubin >2×ULN for age with conjugated/direct bilirubin >20% of the total. Note: Patients with AST or ALT up to 5×ULN are eligible if these elevations are acute and are documented as being directly related to the infectious process being treated
  • Patient has clinically significant abnormal laboratory test results not related to the underlying infection that might expose the patient to risk by participating in the trial, confound the results of the trial, or interfere with the patient's participation for the full duration of the trial
  • Patient is a preterm infant, born at <28 weeks gestational age
  • For Cohorts 1 through 3 only: patient has weight outside of the 5th to 95th percentile based on age
  • Patient is pregnant, breastfeeding, or intends to become pregnant
  • Patient is a newborn with clinically significant anemia who, in the opinion of the investigator, will not be able to tolerate the necessary blood draws to complete the study activities
  • Patient has clinically significant renal, hepatic, or hemodynamic instability
  • Patient is unable or unwilling, in the opinion of the investigator, to comply with the protocol

Where in United States

  • University Of Texas Medical Branch At GalvestonGalveston, United StatesContact: ISTX Clinical TrialsTaking people
  • ECU Brody School of MedicineGreenville, United StatesContact: ISTX Clinical TrialsTaking people
  • UCLA Medical CenterLos Angeles, United StatesContact: ISTX Clinical TrialsTaking people
  • Rady Children's HospitalSan Diego, United StatesContact: ISTX Clinical TrialsTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

The 6 groups in the trial

  • Cohort 1Treatment being tested

    Pediatric patients 12 years to \<18 years of age Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours)

    Treatment: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

  • Cohort 2Treatment being tested

    Pediatric patients 6 years to \<12 years of age Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours)

    Treatment: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

  • Cohort 3Treatment being tested

    Pediatric patients 1 year to \<6 years of age

    Treatment: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

  • Cohort 4Treatment being tested

    Pediatric patients 3 months to \<1 year of age

    Treatment: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

  • Cohort 5 Subgroup 1Treatment being tested

    Aged 2 months to \<3 months, term and preterm (gestational age \>28 weeks) Term infants will receive 25mg/kg SUL and 25mg/kg DUR Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR

    Treatment: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) and Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)

  • Cohort 5 Subgroup 2Treatment being tested

    Aged birth to \<2 months, term and preterm (gestational age \>28 weeks and post-natal age \>7 days) Term infants will receive 25mg/kg SUL and 25mg/kg DUR Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR

    Treatment: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) and Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sulbactam-Durlobactam in Hospitalized Pediatric Patients From Birth to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Acinetobacter Baumannii-calcoaceticus Complex Infection
Record updated
6 October 2026